Lipodystrophy and metabolic complications

Reversibility of lipoatrophy in HIV patients 2 years after switching from a thymidine analogue to abacavir

2 June 2004. Related: Side effects, Lipodystrophy and metabolic complications.

Diabetes and HIV and HCV; aging/HIV and diabetes

2 May 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

FDA panel recommends approval of New-fill

2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.

Lipodystrophy regresses in three patients switched to atazanavir

2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.

Low-dose rHGH maintains reductions in abdominal fat for 60 weeks

3 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Rosiglitazone shows no benefit for lipoatrophy

2 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Importance of dietary management in treating lipid disorders: soy diets may offer comparable effect as statins

3 February 2004. Related: Side effects, Lipodystrophy and metabolic complications.

Human histology and persistence of various injectable filler substances for soft tissue augmentation

3 February 2004. Related: Lipodystrophy and metabolic complications.

Lower doses of d4T produce similar efficacy and reduced side effects

1 December 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Polylactic acid (New-gill) repairs facial wasting and improves quality of life

1 December 2003. Related: Lipodystrophy and metabolic complications.

Canadian study shows increased interventional cardiovascular procedures associated with HAART

1 November 2003. Related: Lipodystrophy and metabolic complications.

New guidelines for the evaluation and management of dyslipidaemia in HIV patients on HAART (2003)

1 October 2003. Related: Lipodystrophy and metabolic complications.

Treatments for lipoatrophy. Are there improvements? Are they noticeable?

1 October 2003. Related: Lipodystrophy and metabolic complications.

Rosiglitazone significantly increases triglyceride and cholesterol levels and does not improve HAART-associated lipoatrophy

1 October 2003. Related: Lipodystrophy and metabolic complications.

US approves and Europe rejects Serostim (recombinant growth hormone) for treatment of HIV-related wasting

1 October 2003. Related: Lipodystrophy and metabolic complications.

5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris

1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.

Underlying mechanisms: adipocytes and cytokines

1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications, Basic science and immunology.

More mitochondrial DNA depletion

1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.

IMT and cardiovascular risk

1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.

Reduced bone mineral density in HIV-positive women

1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.

Rosiglitazone with insulin resistance

1 September 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Additional benefits of exercise with metformin

1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.

Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir

1 September 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.

Facial fat loss – measuring and treatment

1 September 2003. Related: Conference reports, Treatment access, Lipodystrophy and metabolic complications.

Uridine treatment for mitochondrial toxicity

1 September 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Breast enlargement in men and testosterone treatment

1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.

Treatment interruption: a real choice

1 September 2003. Related: Conference reports, Treatment strategies, Lipodystrophy and metabolic complications.

HIV and heart disease: D:A:D prevalence rates show importance of accessing CVD risk in HIV patients

1 July 2003. Related: Lipodystrophy and metabolic complications.

HAART increases body fat at first; both d4T and AZT lead to subsequent fat loss

1 July 2003. Related: Lipodystrophy and metabolic complications.

Lipoatrophy improved by switching from d4T to abacavir

1 July 2003. Related: Lipodystrophy and metabolic complications.

Metabolic abnormalities in protease inhibitor-treated and protease naïve children

1 July 2003. Related: Paediatric care, Lipodystrophy and metabolic complications.

High levels of gout may be linked to HAART

1 June 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women

1 June 2003. Related: Lipodystrophy and metabolic complications.

Statins and fibrates both relatively effective for PI-induced hyperlipidemia

1 May 2003. Related: Lipodystrophy and metabolic complications.

Pioglitazone subjectively improves body shape abnormalities

1 May 2003. Related: Lipodystrophy and metabolic complications.

Conference has strong emphasis on women

1 April 2003. Related: Conference reports, Women's health, Lipodystrophy and metabolic complications, Cancer and HIV.

Approaches to treatment of lipodystrophy

1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Surgery for buffalo hump shows variable results depending on method

1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump

1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

HAART to HEART: cardiovascular risk in HIV

1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss

1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Bone loss and fat loss are closely related in HIV patients on HAART

1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Reduced testosterone levels in HIV-positive women

1 April 2003. Related: Women's health, Lipodystrophy and metabolic complications, Other news.

30-year study links vitamin A to risk of fracture in humans

1 March 2003. Related: Lipodystrophy and metabolic complications.

Bone turnover elevated in HIV-positive patients and linked to duration of HAART

1 March 2003. Related: Lipodystrophy and metabolic complications.

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

1 March 2003. Related: Side effects, Lipodystrophy and metabolic complications.

HIV protease inhibitors promote atherosclerosis independent of dyslipidemia

1 March 2003. Related: Side effects, Lipodystrophy and metabolic complications.

HAART-associated hyperlipidaemia linked to low risk for cardiovascular disease (CVD)

1 March 2003. Related: Lipodystrophy and metabolic complications.

Patient on human growth hormone develops tumours with growth hormone receptors

1 March 2003. Related: Lipodystrophy and metabolic complications.

Review of trials shows testosterone increases lean body mass, and is most effective when given intramuscularly

1 March 2003. Related: Lipodystrophy and metabolic complications.

An overview of the conference

1 February 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.

Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients

1 February 2003. Related: Conference reports, Antiretrovirals, Side effects, Lipodystrophy and metabolic complications.

Adipose tissue alterations develop early in antiretroviral therapy

1 February 2003. Related: Lipodystrophy and metabolic complications.

Perspectives on hormonal, mitochondrial and metabolic changes

1 December 2002. Related: Side effects, Lipodystrophy and metabolic complications.

IAS panel issues first guidelines for HIV and HIV drug-related metabolic complications (2002)

1 December 2002. Related: Side effects, Lipodystrophy and metabolic complications.

Lipodystrophy and adverse drug reaction data presented at the 42nd ICAAC

13 November 2002. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

A range of treatments for facial lipoatrophy

13 November 2002. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Tamoxifen for male breast enlargement?

13 November 2002. Related: Side effects, Lipodystrophy and metabolic complications.

Diet can help reduce lipid levels in people with HAART-related dyslipemia

13 November 2002. Related: Side effects, Lipodystrophy and metabolic complications.

Lipodystrophy syndrome and self-assessment of wellbeing and physical appearance in HIV-positive patients

1 November 2002. Related: Side effects, Lipodystrophy and metabolic complications.

Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy

11 September 2002. Related: Side effects, Lipodystrophy and metabolic complications.

Post navigation